Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Ash 2020 preview – Novartis touts its Tasigna follow-on
Pivotal data at the upcoming Ash conference make Novartis’s asciminib one of the highlights for oncology watchers.
